Thank you for Subscribing to Life Science Review Weekly Brief
Fremont, CA: The COVID-19 pandemic has resulted in unprecedented – and, in some cases, permanent – changes in healthcare delivery.
In the US, 23 percent of all adults—more than 54 million people—have arthritis and x-rays are sometimes utilized to diagnose these patients. With this new partnership, Radiobotics will provide its FDA-cleared technology, RBknee, for users of the TeleRay platform to automatically analyze knee x-rays for signs of osteoarthritis.
TeleRay CEO Tim Kelley believes that Artificial Intelligence is the ideal complement to TeleRay's existing service delivery and will enable TeleRay to provide even more value to the customers they already serve. "We are always looking for innovative ways to serve our customers' needs and we see an increasing demand for AI in Radiology.
Our world-leading platform is now AI-enabled and having products like RBknee unlocked for our customers is central to the TeleRay vision."Radiobotics and TeleRay's primary mission is to reduce healthcare costs. TeleRay extends the reach of Radiobotics AI to those who would not otherwise be able to use such advanced diagnostic applications. As TeleRay CTO Cody Neville comments- "Access to AI in remote and rural areas is unheard of. Although we are networked with 80 percent of top 100 hospitals in the US, we expect to reach and help the professionals and patients who normally wouldn't have this benefit at such a low cost." He continued, "Lowering healthcare cost and serving those in massively underserved markets is our focus." He went on to discuss TeleRay's mission to build a global healthcare communications network with AI that meets the needs of all clinicians, patients, providers, and other developments such as musculoskeletal radiology.